CARE Ratings Ltd Downgraded to Sell Amid Technical Weakness and Valuation Concerns

Quality Assessment: Steady Fundamentals but Growth Concerns

CARE Ratings continues to demonstrate robust financial health with a low average Debt to Equity ratio of zero, underscoring a conservative capital structure. The company has delivered positive results for ten consecutive quarters, with a notable Return on Capital Employed (ROCE) at 24.14% in the half-year period, and a strong cash and cash equivalents position of ₹286.60 crores. Profit Before Tax excluding other income (PBT less OI) has grown at an impressive 33.98% quarterly, reflecting operational efficiency.

However, the long-term growth trajectory raises concerns. Over the past five years, net sales have grown at a modest annual rate of 14.00%, while operating profit has increased by 18.68%. This growth pace is considered subpar relative to sector benchmarks and investor expectations for a capital markets ratings firm. The company’s Return on Equity (ROE) stands at 17.7%, which, while respectable, does not fully justify the current premium valuation.

Valuation: Premium Pricing Amid Mixed Returns

CARE Ratings is currently trading at a Price to Book (P/B) ratio of 5.5, categorising it as very expensive compared to its peers and historical averages. This premium valuation is partly supported by the company’s strong profit growth of 35.6% over the past year and a PEG ratio of 0.8, which suggests some undervaluation relative to earnings growth. Nonetheless, the elevated P/B ratio signals that investors are paying a significant premium for the stock, which may limit upside potential in the near term.

In terms of market performance, the stock has outperformed the Sensex over the last year, generating a return of 31.18% compared to the benchmark’s 10.60%. Over longer horizons, CARE Ratings has delivered exceptional returns, with a 5-year return of 232.10% versus Sensex’s 67.42%. Despite this, the recent one-week and one-month returns have lagged, with the stock declining 2.24% in the past week against a flat Sensex and rising only 0.82% in the last month compared to Sensex’s 2.15% gain.

Financial Trend: Positive Quarterly Results but Slowing Momentum

The company’s latest quarterly results for Q3 FY25-26 were positive, reinforcing its operational strength. Institutional investors hold a significant 54.3% stake, indicating confidence from sophisticated market participants who typically conduct thorough fundamental analysis. This institutional backing provides some stability amid market volatility.

However, the broader financial trend is mixed. While quarterly growth metrics remain encouraging, the relatively slow long-term sales and profit growth rates temper enthusiasm. The stock’s year-to-date return of -1.13% also suggests some recent softness, contrasting with the broader market’s negative 2.26% return over the same period.

Technical Analysis: Shift to Mildly Bearish Signals

The downgrade to Sell is largely driven by a deterioration in technical indicators. CARE Ratings’ technical trend has shifted from sideways to mildly bearish, signalling potential near-term weakness. Key technical metrics reveal a complex picture:

• MACD: Both weekly and monthly charts indicate a mildly bearish stance, suggesting weakening momentum.
• RSI: The weekly RSI shows no clear signal, but the monthly RSI is bearish, indicating possible oversold conditions or downward pressure.
• Bollinger Bands: Weekly bands remain sideways, but monthly bands show mild bullishness, reflecting some volatility and mixed momentum.
• Moving Averages: Daily moving averages are bearish, reinforcing short-term negative sentiment.
• KST (Know Sure Thing): Weekly readings are bullish, but monthly KST is mildly bearish, highlighting conflicting signals across timeframes.
• Dow Theory: Weekly trend is mildly bullish, but no clear monthly trend is established.
• On-Balance Volume (OBV): Weekly OBV shows no trend, while monthly OBV is bullish, indicating accumulation over the longer term despite short-term selling pressure.

These mixed technical signals, combined with recent price action — the stock closed at ₹1,582.80 on 24 Feb 2026, down 1.64% from the previous close of ₹1,609.25 — have contributed to the cautious stance. The stock’s 52-week range remains wide, with a high of ₹1,964.80 and a low of ₹1,057.65, reflecting significant volatility.

Comparative Performance and Market Context

CARE Ratings operates within the capital markets sector, a space characterised by cyclical trends and sensitivity to economic conditions. While the company has outperformed the BSE500 index consistently over the last three years, recent underperformance relative to the Sensex and a shift in technical momentum suggest investors should exercise caution.

The company’s Mojo Grade has been downgraded from Hold to Sell, with a current Mojo Score of 48.0. The Market Cap Grade remains at 3, indicating a mid-tier market capitalisation relative to peers. This downgrade reflects a comprehensive reassessment of the company’s valuation, financial trends, and technical outlook.

Investor Takeaway: Balanced View Amid Mixed Signals

Investors considering CARE Ratings should weigh the company’s strong financial foundation and consistent quarterly performance against its expensive valuation and recent technical weakness. The stock’s premium Price to Book ratio and slowing long-term growth rates suggest limited margin of safety at current levels.

While institutional ownership at 54.3% provides some confidence in the company’s fundamentals, the downgrade to Sell signals that the risk-reward profile has shifted. The mildly bearish technical indicators and recent price declines caution against aggressive accumulation at this stage.

Long-term investors may find value in CARE Ratings’ consistent returns over five and ten years, but near-term traders should monitor technical trends closely. The stock’s performance relative to the Sensex and sector peers will be critical in determining its trajectory in the coming quarters.

Summary of Rating Change

On 23 Feb 2026, CARE Ratings Ltd’s investment rating was downgraded from Hold to Sell, reflecting:

• Quality: Stable fundamentals but modest long-term growth.
• Valuation: Very expensive with a P/B of 5.5 and premium pricing.
• Financial Trend: Positive quarterly results but slowing momentum and mixed returns.
• Technicals: Shift from sideways to mildly bearish trend with multiple indicators signalling caution.

Investors should consider these factors carefully when evaluating CARE Ratings as part of their portfolio strategy.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →